Therapeutics Company Reports Positive Phase 2 Trial Data For Virus Treatment

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company, recently shared positive data from the Phase 2 NAVAL-1 trial, which focuses on relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) peripheral T-cell lymphoma (PTCL). This article aims to provide a comprehensive overview of the trial results, regulatory progress, and Viracta's updated clinical development plan for their promising therapy, Nana-val. $Viracta Therapeutics (VIRX.US)$